Approach: Engineered and targeted cytokines to treat autoimmune diseases
Strategic Area: Immunotherapies
T1D Funding Impact: Bringing T1D focus and experience to a multi-indication drug
Strategic Area: Immunotherapies
T1D Funding Impact: Bringing T1D focus and experience to a multi-indication drug
Location: France, Ile-de-France, Paris
Total raised: $10.54M
Investors 5
| Date | Name | Website |
| 06.02.2022 | Takeda Ven... | takeda.com |
| 02.08.2022 | T1D Fund | t1dfund.or... |
| - | Fund+ | fundplus.b... |
| - | Bioqube Ve... | bioqubeven... |
| 18.04.2022 | Life Scien... | lspvc.com |
Funding Rounds 1
| Date | Series | Amount | Investors |
| 24.04.2025 | - | $10.54M | - |
Mentions in press and media 14
| Date | Title | Description |
| 06.06.2025 | Egle Therapeutics to Present Clinical Trial Progress Poster on Phase I/II EGL-121 Study for EGL-001 at 2025 ASCO Annual Meeting | Paris, France, May 30th 2025 – Egle Therapeutics, a clinical-stage biotechnology company developing therapies targeting regulatory T cells (Tregs) for immuno-oncology and autoimmune diseases, today announced a poster presentation at the upc... |
| 12.05.2025 | Egle Therapeutics to Highlight Novel Preclinical Findings for Regulatory T Cells Targeting Programs EGL-001 and EGL-002 With Poster Presentations at the 2025 AACR Annual Meeting | PARIS–(BUSINESS WIRE)–Egle Therapeutics, a clinical-stage biotechnology company developing therapies targeting regulatory T cells (Tregs) for immuno-oncology and autoimmune diseases, will present two posters at the American Association for ... |
| 24.04.2025 | Egle Therapeutics Receives €9.3 Million in State Funding Under the “Innovations in Biotherapies and Bioproduction” Call for Projects from France 2030 | Egle Therapeutics receives significant non-dilutive funding to accelerate the clinical development of its lead immuno-oncology therapeutic candidate, EGL-001, as part of the “Innovations in Biotherapies and Bioproduction” call for projects ... |
| 19.03.2025 | Egle Therapeutics Secures €9.3 Million to Advance Immuno-Oncology Research | Egle Therapeutics is on the rise. The Paris-based biotechnology company has just secured €9.3 million in state funding. This investment comes from the French government’s France 2030 initiative, specifically under the “Innovations in Biothe... |
| 18.03.2025 | Egle Therapeutics: €9.3 Million In State Funding Raised To Develop Therapies Targeting Regulatory T Cells | Egle Therapeutics, a clinical-stage biotechnology company developing therapies targeting regulatory T cells (Tregs) for immuno-oncology and autoimmune diseases, announced that it secured €9.3 million in state funding under the Innovations i... |
| 18.03.2025 | Egle Therapeutics Raises €9.3M in State Funding | Egle Therapeutics, a Paris, France-based clinical-stage biotechnology company developing therapies targeting regulatory T cells (Tregs) for immuno-oncology and autoimmune diseases, raised €9.3M in state funding. The funding was provided und... |
| 15.01.2025 | Egle Therapeutics Strengthens its Executive Leadership Team With the Appointment of Christophe Quéva, Ph.D., as Chief Executive Officer | Paris, France, January 13, 2025 – Egle Therapeutics, a clinical-stage biotechnology company advancing the next generation of regulatory T cell (Treg)-focused therapies for oncology and autoimmune diseases, today announced the appointment of... |
| 07.09.2024 | Egle Therapeutics to present novel immunocytokine preclinical data for EGL-001 with poster presentation at the 2024 AACR Annual Meeting | April 04, 2024 03:30 PM Eastern Daylight Time Egle Therapeutics to present novel immunocytokine preclinical data for EGL-001 with poster presentation at the 2024 AACR Annual Meeting In the poster, entitled “EGL-001 is a novel immunocytokine... |
| 07.09.2024 | EGLE Therapeutics Strengthens its Leadership Team with the Appointment of Pejvack Motlagh, MD, MSc, as Chief Medical Officer and its Board of Directors with Appointment of John Celebi, MBA, as Indepen... | Paris, France, May [date], 2024 – EGLE Therapeutics, a clinical-stage biotechnology company uniquely positioned to advance the next generation of regulatory T cell-focused therapies for oncology and auto-immunity, announced today the appoin... |
| 10.04.2024 | EGLE announces $320,000 grant opportunity for community solar projects | The Energy Unit of the Michigan Department of Environment, Great Lakes, and Energy (EGLE) is offering grants to help address communities’ roadblocks to clean energy access. At least $320,000 in funding is expected to be available through th... |
Show more